85. Idiopathic interstitial pneumonia Clinical trials / Disease details

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-004404-19-GB (EUCTR)	07/05/2014	25/03/2014	Effect of Fostair® on biomarkers of platelet adhesion in Idiopathic pulmonary fibrosis	A Randomized, Double-blind, Placebo-controlled, Crossover Study toAssess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pulmonary fibrosis. - Effect of Fostair® pMDI on biomarkers of platelet adhesion in IPF	Idiopathic pulmonary fibrosis MedDRA version: 16.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Fostair INN or Proposed INN: beclometasone dipropionate INN or Proposed INN: formoterol fumarate dihydrate	Hull and East Yorkshire Hospitals NHS Trust	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
2	NCT02048644 (ClinicalTrials.gov)	March 2014	23/1/2014	Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis	A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: fostair;Drug: placebo	Hull University Teaching Hospitals NHS Trust	Chiesi Farmaceutici S.p.A.	Completed	40 Years	85 Years	All	20	Phase 2	United Kingdom